1. patients with symptoms of moderate or higher in the severity classification presented by fda have evidence of lower respiratory tract infection in their imaging findings or need supplemental oxygen therapy or mechanical respiration (ie, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc) 2. subjects with infectious diseases such as bacteremia or severe pneumonia requiring active treatment within four weeks prior to the ip administration

1. patients with symptoms of moderate or higher in the severity classification presented by fda have evidence of lower respiratory tract infection in their imaging findings or need supplemental oxygen therapy or mechanical respiration (ie, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc) 2. subjects with infectious diseases such as bacteremia or severe pneumonia requiring active treatment within four weeks prior to the ip administration

patients with symptoms of moderate or higher in the severity classification presented by fda have evidence of lower respiratory tract infection in their imaging findings or need supplemental oxygen therapy or mechanical respiration (ie, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc) subjects with infectious diseases such as bacteremia or severe pneumonia requiring active treatment within four weeks prior to the ip administration

patients with symptoms of moderate or higher in the severity classification presented by fda have evidence of lower respiratory tract infection in their imaging findings or need supplemental oxygen therapy or mechanical respiration (ie, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc) subjects with infectious diseases such as bacteremia or severe pneumonia requiring active treatment within four weeks prior to the ip administration

1. patients with symptoms of moderate or higher in the severity classification presented by fda have evidence of lower respiratory tract infection in their imaging findings or need supplemental oxygen therapy or mechanical respiration (ie, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc) 2. subjects with infectious diseases such as bacteremia or severe pneumonia requiring active treatment within four weeks prior to the ip administration

1. patients with symptoms of moderate or higher in the severity classification presented by fda have evidence of lower respiratory tract infection in their imaging findings or need supplemental oxygen therapy or mechanical respiration (ie, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc) 2. subjects with infectious diseases such as bacteremia or severe pneumonia requiring active treatment within four weeks prior to the ip administration